Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Booster battle: moderna vs. novavax for fourth COVID shot

NCT ID NCT05658523

Vaccine Sponsor: Murdoch Childrens Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two different COVID-19 vaccines—Moderna's bivalent mRNA and Novavax's protein-based—as a fourth booster dose in healthy adults who have already had three doses. Researchers will check how well each vaccine boosts the immune system and track any side effects. The goal is to find out which booster is safer and more effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
COVID-19 vaccines (Moderna bivalent mRNA and Novavax protein-based)
What this could lead to
If successful, this could show which booster vaccine works best for a fourth dose, helping guide future vaccination strategies.
What could go wrong
This is a relatively small trial (496 people) and only measures short-term immune response and side effects, not long-term protection against infection or severe disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

496 people

The number who actually took part.

Started

Feb 2023

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Have received three doses of COVID-19 vaccines at least 6 months earlier. 2. No confirmed SARS-CoV-2 infection on PCR or RAT within the last 3 months. 3. Willing and able to give written informed consent. 4. Aged 18 years or above. 5. Willing to complete the follow-up requirements of the study. Exclusion Criteria: 1. Currently receiving immunosuppressive medication or anti-cancer chemotherapy. 2. Known HIV infection. 3. Congenital immune deficiency syndrome. 4. Received immunoglobulin or other blood products in the three months prior to potential study booster vaccination. 5. Study staff and their relatives. 6. Have a history of a severe allergic reaction to any COVID-19 vaccines or have a medical exemption to receiving further COVID-19 vaccines. 7. Cannot read or understand English.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

  • Royal Children's Hospital, Murdoch Children's Research Institute

    Melbourne, Victoria, 3052, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.